Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Omeprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 6/20 | 0.59 |
| ▸ | ATP4B known ✓ | P51164 | 6/20 | 0.59 |
| ▸ | BRS3 | P32247 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.59 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.59 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.59 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.59 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.59 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.59 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.59 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.59 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.59 |
| ▸ | WDR5 | P61964 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.59 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Esomeprazole SCHEMBL30426884 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL28256108 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL1192 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29360040 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL140006 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL19535 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Esomeprazole SCHEMBL29691369 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL29772327 | 0.99 | BRS3 (0.62) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2871344 | 0.98 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 | |
| Omeprazole SCHEMBL2517856 | 0.98 | BRS3 (0.61) | BRS3ATP4AATP4BCYP2C9ATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155435-A1 | Kit for Treatment of Upper Gastrointestinal Tract Conditions | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-05 | — | — | US | claimed |
| WO-2005082888-A1 | PROCESS FOR THE PREPARATION OF MAGNESIUM SALT OF OMEPRAZOLE | MILEN MERKEZ ILAC ENDUSTRISI A.S. (TR) | 2005-09-09 | — | — | WO | claimed |
| WO-2005018640-A1 | KIT FOR TREATMENT OF UPPER GASTROINTESTINAL TRACT CONDITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043359-A1 | Gastric juice antisecretory agents ; interior and exterior multilayer container | THE PROCTER & GAMBLE COMPANY (US) | 2005-02-24 | — | — | US | claimed |
| US-20030203018-A1 | Stable oral pharmaceutical dosage forms | SAGE PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | claimed |
| US-20010006649-A1 | STABLE ORAL PHARMACEUTICAL DOSAGE FORMS | SAGE PHARMACEUTICALS, INC. | 2001-07-05 | — | — | US | claimed |
| WO-1998050019-A1 | STABLE ORAL PHARMACEUTICAL DOSAGE FORMS | SAGE PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | claimed |
| EP-4331572-A2 | PEDIATRIC SUSPENSION FORMULATION | Xeolas Pharmaceuticals Ltd. (IE) | 2024-03-06 | — | — | EP | disclosed |
| US-20230390266-A1 | PEDIATRIC SUSPENSION FORMULATION | Xeolas Pharmaceuticals Ltd. (IE) | 2023-12-07 | — | — | US | disclosed |
| US-11826359-B2 | Pediatric suspension formulation | Xeolas Pharmaceuticals Ltd. (IE) | 2023-11-28 | — | — | US | disclosed |
| EP-3799861-B1 | PEDIATRIC SUSPENSION FORMULATION | XEOLAS PHARMACEUTICALS LTD (IE) | 2023-11-22 | — | — | EP | disclosed |
| CN-114929222-A | Pediatric suspension formulation | 希奥拉斯制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021064682-A1 | PEDIATRIC SUSPENSION FORMULATION | Xeolas Pharmaceuticals Ltd. (IE) | 2021-04-08 | — | — | WO | disclosed |
| WO-2006073779-A1 | NOVEL OMEPRAZOLE FORMS AND RELATED METHODS | TRANSFORM PHAMACEUTICALS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2005082888-A1 | PROCESS FOR THE PREPARATION OF MAGNESIUM SALT OF OMEPRAZOLE | MILEN MERKEZ ILAC ENDUSTRISI A.S. (TR) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005018640-A1 | KIT FOR TREATMENT OF UPPER GASTROINTESTINAL TRACT CONDITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043359-A1 | Gastric juice antisecretory agents ; interior and exterior multilayer container | THE PROCTER & GAMBLE COMPANY (US) | 2005-02-24 | — | — | US | disclosed |
| US-4738974-A | Base addition salts of omeprazole | AKTIEBOLAGET HASSLE (SE) | 1988-04-19 | — | — | US | disclosed |
| EP-0124495-B1 | OMEPRAZOLE SALTS | Aktiebolaget Hässle (SE) | 1987-01-14 | — | — | EP | disclosed |
| EP-0124495-A2 | Omeprazole salts | Aktiebolaget Hässle (SE) | 1984-11-07 | — | — | EP | disclosed |